Ben Holm
24 Mar 2018
Re: Any chartists Hi Luppo,There is a consolidation between abt 1260 and 1370 which isn't a W but is still potentially a base. As and when 1370 is properly penetrated the base is complete and the minimum upside expected would be to 1480 on a repetition of the amplitude of the base formation. Given that the longterm neckline is at 1455 at least a pause at that level is likely. More resistance is evident at 1530. But it won't be easy with such a big top 1450 to 1725 formed after the sharp fall in November last year. But the quick rebound off the Oct 2015 support level is a hopeful sign that momentum is back in the hands of the buyers.
Bill1703
23 Mar 2018
Re: GKS withdraws bidding "... clears the way for the Novartis deal which GSK have wanted all along... Which I predicted sometime ago I might just add... Of course this is clever by seeming to go for this and then pulling back it's doing Emma's standing with the market no harm at all."Yes, all credit SM. I was more 50/50 on it, partly as I was always very dubious that RB could go for it at all, given the (relative) hole they've got themselves into.It is a moot point - and we will likely never really know - just how seriously GSK considered it. Of course you "have a look" (in EW's words), and there was nothing to lose by playing along as long as no commitment was demanded - it is instructive, probably, that they (and RB) pulled out at the point where binding bids were required. And now, at the very least, they'll know quite a bit more about a major competitor portfolio in the consumer healthcare business.So both GSK and RB now play the M&A "discipline" card - but really, for both it's 'virtue of necessity' territory. I seriously doubt, if they both hadn't already been under pressure created (largely) from their own underwhelming performance and/or execution elsewhere, that they both wouldn't be chasing this further, and harder.And then there's poor old Pfizer, left holding the baby... Perhaps that's what you get for telling the world you've lost interest in an ex-growth business, and then expecting a fancy price for it from the "greater fool". There's a lesson here also for the likes of Nick Train, and the argument that big established brands will always send buyers into a high-multiple feeding frenzy, no matter the underlying financial dynamics. At least Unilever got it, with their Spreads biz - they kept expectations low for a mature, ex-growth operation, and no-one worried too much when they merely matched them with the final (comparatively modest) price, even in what looked like a highly competitive auction.
sound money
23 Mar 2018
Re: GKS withdraws bidding Yes good news. This now clears the way for the Novartis deal which GSK have wanted all along.Which I predicted sometime ago I might just add.Of course this is clever by seeming to go for this and then pulling back it's doing Emma's standing with the market no harm at all. M
susanne9
23 Mar 2018
good news My second small piece of good news this week raising the SP on GSK. The first was related, being RB also pulling out of the deal and their share price rising too. Apart from that everything disaster - my SIPP worst performing week for 2 years.
TwoSporrans
23 Mar 2018
Re: GKS withdraws bidding Great news !This pretty much secures the dividend heading 2019 onwards.Guess a trimming still possible, if debt paydown proves challenging.... but fear of a slashing fully assuaged.When I saw the GSK price well up this morning, thought Walmsey had announced thus.Carnage just about everywhere else.Even e.g. UK REITS knocked down. Global trade War = Deep equity Bear market.Just hope Trump is mostly playing sops to his electoral base; might backslide somewhat like on the steel/AL tariffs.Chinese response very restrained...thus far.
gamesinvestor
23 Mar 2018
Re: GKS withdraws bidding I thought this might happen - good move - it appears Emma might be smarter than a lot of other gung ho CEOs.I might buy back into this one - well might anyhow !!Games
IOMINVESTCOM
23 Mar 2018
Re: GKS withdraws bidding GSK update regarding Pfizer Inc. Consumer HealthcareGlaxoSmithKline plc (LSE/NYSE: GSK) today confirms it has withdrawn from the process relating to Pfizer's Consumer Healthcare business.Emma Walmsley, Chief Executive Officer, GSK said:"While we will continue to review opportunities that may accelerate our strategy, they must meet our criteria for returns and not compromise our priorities for capital allocation."GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
IOMINVESTCOM
23 Mar 2018
GKS withdraws bidding nm
IOMINVESTCOM
23 Mar 2018
Pole position in race for £14bn [link]
Watfordhornet
22 Mar 2018
Re: Pfizer auction - FURTHER Not a surprise regarding timing.Final bids are in so why show hand b4. Surely in their interests to get GSK to pay more so they rightly kept quiet until bids submitted
Bill1703
22 Mar 2018
Re: Pfizer auction - FURTHER "Oh dear - GSK can't seriously want to load themselves up with it surely? Maybe they will also pull out in such a nervous market.. Sigh of relief for my investment in RB though."Time will tell, Games. Could go either way IMHO.Absent further twists in the story, GSK are now sole remaining bidder in the auction - for a business where they should be able to capture chunky synergies. This is rarely a bad position to be in! But it'd still be a big deal for a company under some pressure, and which has clearly committed its priority to investing elsewhere in the group.I'd be okay with GSK getting it, via their JV structure, at a reasonable price, ie. no more than the low-end of the public range, and ideally a bit less. But the chance of Pfizer pulling the auction and keeping the biz has obviously gone up - not ideal for them, but they'll know that having only one bidder in an auction is not a position of strength. I also think the hybrid solution previously mooted - Pfizer joining the existing GSK consumer JV - is increasingly interesting as a potential 'win-win' compromise.RB are making a virtue of a necessity in pulling out - they were (relatively suddenly) on the back foot, given both balance sheet and tarnished reputation. They had no support for doing the deal, as their SP reflected. Hence the curious formal statement which they didn't need to make, having said nothing formally about it before.
gamesinvestor
22 Mar 2018
Re: Pfizer auction - FURTHER Oh dear - GSK can't seriously want to load themselves up with it surely?Maybe they will also pull out in such a nervous market.Sigh of relief for my investment in RB though.Games
EssentialInvestor
21 Mar 2018
Re: Pfizer auction - FURTHER Looks like last man standing if tonight's FT report is accurate.Nice day for RB tomorrow perhaps, GSK may be bumpy!.
Hardboy
20 Mar 2018
Re: Trump Drug Pricing Plans "Anybody know more about Trumps plans (on drug pricing plans)"I saw him saying in a speech yesterday that he's ready to execute drug dealers. I hope that doesn't include GSK staff.
PrefInvestor1
20 Mar 2018
Trump Drug Pricing Plans Hi All,Heard part of a piece on the news yesterday that Trump plans to unveil his drug pricing plans shortly. Previously I think that he had stated that he wanted to bring down prices significantly, which clearly wouldnt be good for the likes of GSK.I have a few and was planning to add some more (given my newly found cash from exiting prefs !) but I think Ill hang on for the moment.Anybody know more about Trumps plans in this area ?.ATBPref (no longer)
